STOCK TITAN

Cytosorbents Corp - CTSO STOCK NEWS

Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.

CytoSorbents Corporation (NASDAQ: CTSO) develops life-saving blood purification technologies for critical care and cardiac surgery patients. This dedicated news hub provides investors and medical professionals with essential updates about the company’s clinical advancements, regulatory milestones, and strategic initiatives.

Access timely information on earnings reports, product launch announcements, and partnership developments related to CytoSorb® and other polymer adsorption therapies. Our curated collection includes press releases about clinical trial outcomes, European Union regulatory updates, and innovations in cytokine storm management.

Bookmark this page to monitor CTSO’s progress in advancing critical care solutions while staying informed about financial performance and market positioning. Check regularly for verified updates directly from corporate communications and trusted financial news sources.

Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) has successfully completed its MISSION 100,000 fundraising campaign, raising $100,000 for the humanitarian organization CARE to combat COVID-19. This initiative coincides with the milestone of shipping over 131,000 CytoSorb® blood purification cartridges, used in treating severe COVID-19 cases. The funds will aid CARE's Crisis Response Campaign, providing vaccination and sanitation efforts globally. CEO Phillip Chan expressed gratitude for support, emphasizing the importance of corporate partnerships in the fight against the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
covid-19
-
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) will release its second quarter 2021 operating and financial results on August 3, 2021, after market close. The company specializes in blood purification technology to treat critical conditions in intensive care and during cardiac surgery. Following the results announcement, a conference call will occur at 4:30 p.m. ET on the same day. CytoSorbents' flagship product, CytoSorb®, is approved in the EU and has been used in over 131,000 treatments globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences earnings
-
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) has received full FDA approval for its Investigational Device Exemption (IDE) to initiate the pivotal STAR-T trial. This double-blind, randomized trial will evaluate the use of DrugSorb-ATR in removing ticagrelor during cardiothoracic surgery, targeting up to 120 patients at 20 sites across the U.S. The study aims to reduce peri-operative bleeding risks associated with ticagrelor, a medication used in cardiovascular patients. Participant enrollment is expected to commence this summer, with completion anticipated in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.41%
Tags
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) has appointed Terri Anne Powers as Vice President of Investor Relations and Corporate Communications, effective immediately. Powers brings over 15 years of healthcare industry experience, including her recent role at Diplomat Pharmacy and over nine years with Veolia Environnement. In her new position, she aims to enhance the company's visibility and foster dialogue with investors. CytoSorbents, known for its CytoSorb® blood purification technology, seeks to leverage her expertise to communicate its growth story and potential FDA approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
management
-
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) announced its presentation at the Jefferies Virtual Healthcare Conference on June 3, 2021. The company will detail its progress in the field of blood purification technology, specifically its flagship product, CytoSorb®, used to treat critical conditions in patients. Management will also engage in one-on-one meetings with investors throughout the day. A live webcast of the presentation will be available, with an archived replay accessible for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
-
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) announced that its CytoSorb® blood purification technology is now registered and commercially available in Singapore. This approval includes treatments for reducing cytokine storms, bilirubin in liver disease, and myoglobin in trauma cases, following European Union indications. The company expects increased demand due to Singapore's high prevalence of sepsis and cardiovascular diseases. The partnership with distributor Humedical aims to enhance patient care in the region. CytoSorb has been utilized in over 131,000 treatments globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
none
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) has announced its participation in the UBS Global Healthcare Virtual Conference and the Oppenheimer MedTech, Tools, and Diagnostic Summit on May 26, 2021. The company will present an overview of its progress and outlook, along with conducting one-on-one meetings with investors. CytoSorbents specializes in blood purification technology, particularly its CytoSorb® product, which is approved in the EU and utilized in over 131,000 treatments globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
conferences
-
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) secured a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract worth $1.5 million to enhance its K+ontrol™ platform for treating severe hyperkalemia resulting from traumatic injuries. This follows prior Phase I and II successes, accumulating $1.15 million in funding. The technology aims to address life-threatening hyperkalemia in environments lacking modern medical facilities, providing critical treatment in emergencies, particularly for military and mass casualty scenarios.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) reported a 22% revenue increase in Q1 2021, reaching $10.6 million, driven by a 24% growth in CytoSorb product sales to $10.1 million. The company achieved a gross profit margin of 77% and maintained a robust cash balance of $68.5 million. The FDA granted conditional approval for the STAR-T trial, aiming for U.S. regulatory approval. However, COVID-19 related sales dropped to $1.8 million from previous quarters, influenced by European lockdowns. CytoSorbents anticipates ongoing growth in non-COVID-19 business and new product applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
none
Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) will announce its Q1 2021 financial results on May 4, 2021, at 4:45 PM EST. The company specializes in blood purification technology, notably CytoSorb®, aimed at managing inflammation in critically ill patients. A live conference call will follow the results announcement, providing insights into operational and financial progress. CytoSorbents' technology has been utilized in over 121,000 treatments and is approved in the EU for various applications, including COVID-19 management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences earnings
Cytosorbents Corp

Nasdaq:CTSO

CTSO Rankings

CTSO Stock Data

64.38M
57.26M
9.72%
29.71%
2.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PRINCETON